Peer-Reviewed Publication
Mol Cancer Ther2024;23(7):924-938.July 2, 2024Journal Article
Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations.
Funda Meric-Bernstam1, Michael W Lloyd2, Soner Koc3, Yvonne A Evrard4, Lisa M McShane5, Michael T Lewis6, Kurt W Evans1, Dali Li1, Lawrence Rubinstein5, Alana Welm7, Dennis A Dean3, Anuj Srivastava8, Jeffrey W Grover3, Min J Ha9, Huiqin Chen10, Xuelin Huang11, Kaushik Varadarajan12, Jing Wang10, Jack A Roth13, Bryan Welm7, Ramaswamy Govinden14, Li Ding14, Salma Kaochar15, Nicholas Mitsiades16, Luis Carvajal-Carmona17, Meenhard Herylyn18, Michael A Davies19, Geoffrey I Shapiro20, Ryan Fields21, Jose G Trevino22, Joshua C Harrell23, , James H Doroshow24, Jeffrey H Chuang8, Jeffrey A Moscow25
1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
2The Jackson Laboratory, Bar Harbor, Maine.
3Seven Bridges Genomics, Charlestown, Massachusetts.
4Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.
5Biometric Research Program, DCTD, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
6Departments of Molecular and Cellular Biology and Radiology, Lester and Sue Smith Breast Center, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
7Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
8The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.
9Department of Biostatistics, Graduate School of Public Health, Yonsei University, Seoul, Republic of Korea.
10Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
11Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
12Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
13Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
14Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.
15Department of Medicine, Baylor College of Medicine, Houston, Texas.
16Department of Molecular Cellular Biology, Baylor College of Medicine, Houston, Texas.
17Department of Biochemistry and Molecular Medicine, University of California, Davis, California.
18The Wistar Institute, Philadelphia, Pennsylvania.
19Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
20Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
21Department of Surgery, Washington University School of Medicine, St. Louis, Missouri.
22Department of Surgery, Virginia Commonwealth University, Richmond, Virginia.
23Department of Pathology, Virginia Commonwealth University, Richmond, Virginia.
24Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
25Investigational Drug Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Abstract
Although patient-derived xenografts (PDX) are commonly used for preclinical modeling in cancer research, a standard approach to in vivo tumor growth analysis and assessment of antitumor activity is lacking, complicating the comparison of different studies and determination of whether a PDX experiment has produced evidence needed to consider a new therapy promising. We present consensus recommendat…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans